Lazard Asset Management
URGN icon

Lazard Asset Management’s UroGen Pharma URGN Stock Holding History

Lazard Asset Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-56
Closed – – 2545
2025
Q1 		$0 Sell
56
-6,308
-99% -$67.3K ﹤0.01% 2589
2024
Q4 		$67K Buy
+6,364
New +$76.2K ﹤0.01% 1918
2024
Q1 		– Sell
-354
Closed -$5K – 2391
2023
Q4 		$5K Sell
354
-2,957
-89% -$38.4K ﹤0.01% 2122
2023
Q3 		$46K Buy
+3,311
New +$53.1K ﹤0.01% 1886
2023
Q2 		– Sell
-3,111
Closed -$28K – 2549
2023
Q1 		$28K Hold
3,111
– – ﹤0.01% 1970
2022
Q4 		$27K Buy
+3,111
New +$29.5K ﹤0.01% 2076
2021
Q4 		– Sell
-3,281
Closed -$55K – 2472
2021
Q3 		$55K Buy
+3,281
New +$52K ﹤0.01% 1640

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Lazard Asset Management's URGN Position: Q2 2025 in Review

Lazard Asset Management sold out of UroGen Pharma (URGN) in Q2 2025, closing a stake of 56 shares.

Lazard Asset Management first reported a position in URGN in Q3 2021 and held it in 7 quarters. The position peaked at $67K in Q4 2024. 150 funds tracked by Wall St. Rank hold URGN as of Q2 2025.

  • Lazard Asset Management reported no remaining UroGen Pharma position as of Q2 2025 after selling out during the quarter.
  • Lazard Asset Management sold 56 UroGen Pharma shares in Q2 2025.
  • Lazard Asset Management first reported a position in UroGen Pharma in Q3 2021 and held it in 7 quarters.
  • Lazard Asset Management's UroGen Pharma position peaked at $67K in Q4 2024.
  • 150 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2025.

Based on Lazard Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.